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Thyroid disorders in patients with newly
diagnosed rheumatoid arthritis is associated
with poor initial treatment response evaluated
by disease activity score in 28 joints-C-reactive
protein (DAS28-CRP)
An observational cohort study
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∗
, Jørgen Hangaard, PhDc, Inger Marie Jensen Hansen, PhD, DMScia,b,d
Abstract
To determine the prevalence of thyroid disorders among newly diagnosed rheumatoid arthritis (RA) patients and evaluate the
association between clinical characteristics of RA and thyroid disorders, and also initial treatment response in the RA patients with
thyroid disorders.
Newly diagnosed, adult RA patients who were diagnosed according to the new 2010 American College of Rheumatology/
European League Against Rheumatism criteria since January 1, 2010, were included. Patients’ demographic data, serology results
including immunoglobulin M rheumatoid factor (IgM RF), anticyclic citrullinated peptide antibody (anti-CCP), and antinuclear antibody
(ANA), and also disease activity score in 28 joints-C-reactive protein at the time of diagnosis and after 4 months (±1–2 months) of
treatment initiation were extracted from Danish Danbio Registry. Patients’ electronic hospital records for the past 10 years were
reviewed to reveal if they had been diagnosed with thyroid disorders or they had abnormal thyroid test.
In all, 439 patients were included, female 60.1%, mean age 64.6±15.0 years and disease duration 2.6±1.7 years. Prevalence of
thyroid disorders was 69/439 (15.7%) and hypothyroidism was the most frequent disorder (30.4%). The presence of thyroid
disorders among RA patients was signiﬁcantly associated with female sex (P< .001), ANA positivity (P= .04), and anti-CCP≥100EU/
mL (P= .05). Furthermore, RA patients with thyroid disorders had signiﬁcantly poorer initial response to RA treatment compared with
patients with isolated RA after 4 months of treatment (P= .02). There were no associations between thyroid disorders and age,
disease duration, and also IgM RF positivity.
Presence of thyroid disorders in RA patients is suggestive of a more aggressive disease and poor outcome, with direct effect on
initial treatment response. To diagnose concurrent thyroid disorders at an earlier stage, routine measurement of serum thyroid-
stimulating hormone is recommended in all RA patients at the time of diagnosis and with yearly interval thereafter.
Abbreviations: ACR = American College of Rheumatology, ANA = antinuclear antibody, anti-CCP = anticyclic citrullinated
peptide antibody, DAS28-CRP = Disease Activity Score in 28 joints-C-reactive protein, EULAR = European League Against
Rheumatism, IgM RF = immunoglobulin M rheumatoid factor, RA = rheumatoid arthritis, TSH = thyroid stimulating hormone.
Keywords: ANA, anti-CCP, DAS28-CRP, IgM RF, rheumatoid arthritis, thyroid disorders
1. Introduction
Rheumatoid arthritis (RA) is a chronic, autoimmune disease with
a prevalence of 0.5% to 1% in the general population. The
pathogenesis of RA is still not clearly understood. It may be
caused by a complex interaction between genetic and environ-
mental factors resulting in activation of the immune response and
synovial inﬂammation in a distinct symmetric pattern.[1] Even
though RA affects mainly joints, extra-articular involvement can
occur in approximately 40% of patients.[2]
In addition to articular and extra-articular manifestations,
various comorbidities can complicate the course of disease.[3]
Patients with RA are at increased risk of diabetes,[4]
vasculitis,[5] lung diseases[6] and hearing loss,[7] probably due
to autoimmunity, compared with the general population. Other
common comorbidities among patients with RA are cardiovas-
cular events, different types of cancers, depression, and so on.[3]
These comorbid diseases can affect the long-term prognosis and
may decline the functional status, and also life span of the
patients.[3]
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An association between RA and thyroid dysfunction with or
without autoimmune origin has been reported in 6% to 34% of
patients with RA.[8] On the contrary, when presence of thyroid
antibodies is considered, despite normal thyroid function, the
prevalence can rise up to about 38%.[9] These rates are
signiﬁcantly greater when compared with the general population
(about 2–3 times).[8–11] Routine screening of the population for
thyroid disease is not recommended; however, assessment of
high-risk group, for example, patients with abnormal ﬁndings on
physical examination, symptoms suggestive of hyperthyroidism
or hypothyroidism, women with a positive family history of
thyroid disease, previous thyroid dysfunction, and also a history
of other autoimmune disease, for example, type 1 diabetes or
Addison disease, has been encouraged.[12]
Previous studies were in favor of the hypothesis that an
association between thyroid dysfunction and RA exists, probably
due to autoimmunity; however, the results of these studies were
not consistent.[13] Furthermore, most of these studies focused on
the clinical characteristic of thyroid dysfunction, and just a few of
them discussed the impact of thyroid dysfunction on disease
activity and treatment response of RA. The primary objective of
this study was to reveal the prevalence of thyroid disorders
among newly diagnosed RA patients to ﬁnd whether thyroid
disorders are more prevalent among the RA patients. The
secondary objectives of this studywere to evaluate the association
between clinical characteristic of RA and thyroid disorders, and
also to delineate the initial RA treatment response in RA patients
with thyroid disorders, because the initial treatment response has
an independent prognostic value.[14–16] To the best of our
knowledge, this is the ﬁrst study of its kind investigates the
clinical relationship between RA and thyroid disorders.
2. Materials and methods
2.1. Danbio
The Danish Danbio registry was ﬁrstly established in 2000. It
provides nationwide data on the disease course of patients with
inﬂammatory rheumatic disease including RA, ankylosing
spondylitis, and psoriatic arthritis via unique personal identiﬁca-
tion code with 2 signiﬁcant purposes: ﬁrstly, helping clinicians to
improve quality of routine clinical care by providing a disease
chronicle, and secondly, providing a powerful research database.
Danbio has been approved by The Danish Data Registry (j. nr.
2007-58-0014 and j.nr. 2007-58-0006) and National Board of
Health (j. nr. 7-201-03-12/1), and thereafter, since 2006, it
became mandatory to report to the registry. Data are collected
from patients and health personnel (nurses and physicians) and
are basically divided into baseline variables (eg, demographic
data, diagnosis, diseases duration) and longitudinal/follow-up
data (eg, treatment, functional status, and disease activity
scores).[17] In Denmark, all patients with a newly diagnosis of
RA should be registered in Danbio. Each Department of
Rheumatology has access to its own patients. At our department,
all patients with diagnosis of RA are registered in Danbio at every
consultation.
2.2. Study design and setting
This is an observational, cohort, single-center study. All parts of
the study were performed at the Department of Rheumatology,
Svendborg Hospital, Denmark, in December 2015. Ethical
approval was obtained from Danish Data Protection Agency
(ﬁle no.14/50243) and Danish Patient Safety Authority (ﬁle no.3-
3013-1542/1/).
2.3. Participants
All adult patients diagnosed with RA, registered in Danbio by
rheumatologists at our department during outpatient visits, were
considered to enter into the study. The diagnosis of RA was
established according to the new 2010 American College of
Rheumatology (ACR)/European League Against Rheumatism
(EULAR) criteria for RA.[18] Inclusion criteria were as follows:
patients who were registered at the Department of Rheumatolo-
gy, Svendborg hospital, Denmark; adult patients who were
diagnosed with RA since January 1, 2010, according to the new
criteria. Patients who passed away or were referred to the other
departments were also included. Patients who were diagnosed
with RA before January 1, 2010, and juvenile RA were excluded
from the study.
2.4. Initial rheumatoid arthritis treatment
The initial treatment for all newly diagnosed RA patients at our
department is methotrexate, with increasing doses up to 25mg
per week, depending on disease activity score in 28 joints-C-
reactive protein (DAS28-CRP) as an index of disease activity.
Furthermore, treatment can be supplemented by hydroxychlor-
oquine and sulfasalazine, and also prednisolone (given intramus-
cular, intra-articular, or orally) in case of remaining
inﬂammation. The treatment goal is to achieve remission, that
is, DAS28-CRP less than 2.6 (or low disease activity, ie, DAS28-
CRP 3.2) as quickly as possible.
2.5. Data collection
Patients’ demographic data (age, sex, year of diagnosis), serology
test results including immunoglobulinM rheumatoid factor (IgM
RF), anticyclic citrullinated peptide antibody (anti-CCP), and
antinuclear antibody (ANA), and also DAS28-CRP at the time of
diagnosis and after 4 months (±1–2 months) of treatment
initiation were collected. The electronic hospital records of the
patients for the past 10 years were evaluated, to the extent data
were available, for a positive history of thyroid disorders and also
use of thyroid medications and abnormal thyroid laboratory tests
(triiodothyronine [T3], thyroxine [T4], thyroid-stimulating
hormone [TSH]) to clarify if the patients have been diagnosed
with thyroid disorders (hypothyroidism, hyperthyroidism, goiter,
thyroiditis, autoimmune disease) as well. Thyroid peroxidase
antibody (TPOAb), thyroglobulin antibody (TGAb), and
thyrotropin receptor antibody (TRAb) were used to delineate
thyroid autoimmunity. The individual medical records from
family physicians were not examined in this study, because we did
not have access to such records. Diagnoses of thyroid disorders
subgroups were made at the Department of Endocrinology based
on routine follow-up and updated guidelines. Patients with
subclinical thyroid disease, who had increased or decreased TSH,
but normal T3 and/or T4 and no clinical symptoms, were also
included in the statistical analysis.
2.6. Variables
Demographic data were extracted from Danbio. The results of
IgM RF (normal range: <15IU/mL), anti-CCP (normal range:
<20EU/mL), and ANA (normal range: <1.0 IU) were collected
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+0.36 ln(CRP+1)+0.014Global Visual Analog Scale+0.96.
DDAS28-CRP=DAS281-CRP (at the time of diagnosis)
DAS284-CRP (after 4 months of treatment initiation±1–2
months). The lower reporting limit of CRP was considered as
<10mg/L.[19]
In our laboratory, the following reference values were used:
TSH (0.3–4mIU/L), T3 (1.3–2.2nmol/L), T4 (60–130nmol/L),
TPOAb (2–10103 IU/L), TGAb (<60103 IU/L), and TRAb
(<0.7 IU/L).
2.7. The EULAR response criteria
According to the EULAR response criteria an improvement of
DAS28-CRP greater than 1.2 in a patient with a present score of
3.2 was deﬁned as good response. Patients with an improve-
ment of >0.6 to 1.2 and a present score of 5.1, or an
improvement of>1.2 and a present score of greater than 3.2, was
considered to respond moderately to treatment. Nonresponder
patients are categorized as those who had an improvement of
0.6 regardless of DAS28-CRP score, or an improvement of
>0.6 to1.2 and a present score of>5.1.[20] Results ofDDAS28-
CRP were also assessed by the EULAR response criteria.
2.8. Statistical analysis
All statistical analyses were performed using Microsoft Excel
2010. Continuous data were presented as mean± standard
deviation (±SD), and categorical data as frequencies and
respective percentages. Comparisons of the above mentioned
variables, between RA patients with and without thyroid
disorders, were made with Student t test. We used 1-way
analysis of variance (ANOVA) test to elucidate any differences of
mean DDAS28-CRP in subgroups of thyroid disorders. When
comparing 2 binary variables, the chi-square test was performed.
P value was considered as signiﬁcant if P0.05. In case of
missing data, we used pairwise deletion to keep as many cases as
possible for each analysis.
3. Results
Of 974 RA patients registered in the regional part of Danbio, 439
patients had a diagnosis of RA based on the new 2010 ACR/
EULAR criteria and fulﬁlled the inclusion criteria. Five hundred
thirty-ﬁve patients, who were diagnosed with RA before January
1, 2010, were excluded from the study. Demographic and disease
characteristics of included patients are summarized in Table 1.
The prevalence of thyroid disorders was 69/439 (15.7%).
The standard treatment was methotrexate, eventually com-
bined with hydroxychloroquine and sulfasalazine, if needed. In
cases of severe inﬂammation, prednisolone (intra-articular/
intramuscular/oral) was added to the treatment regimen.
The results of our study demonstrated that presence of thyroid
disorders among RA patients is signiﬁcantly associated with
female sex, ANA positivity, and anti-CCP ≥100EU/mL.
Furthermore, RA patients with thyroid disorders had signiﬁcant-
ly poorer initial response to the RA treatment compared with
patients with isolated RA. There was no association between
thyroid disorders and age, disease duration, and also IgM RF
positivity (Table 2).
Hypothyroidism was the most common thyroid disorder with
a prevalence of 21/69 (30.4%). There was no signiﬁcant
difference of mean DDAS28-CRP in subgroups of thyroid
disorders (Table 3).
4. Discussion
This was the ﬁrst cohort study, of its kind, evaluating the initial
response to treatment among RA patient with and without
thyroid disorders. The key results of our study were as follows:
the prevalence of thyroid disorders among our RA patients who
had been in contact with the hospital in the central part of
Denmark was 15.7% that was higher compared to the general
Danish population[21,22]; the presence of thyroid disorders in RA
Table 1
Demographic and disease characteristics of the included patients.
N=439
Age, y, mean±SD 64.6±15.0
Sex, %
Female 264 (60.1%)














No data 27 (6.1%)
DDAS28=DAS281 (at the time of diagnosis)–DAS284 (after 4 months of treatment initiation±1–2
months), ANA= antinuclear antibody, anti-CCP= anticyclic citrullinated peptide antibody, DAS281=
disease activity score in 28 joints at the time of diagnosis, DAS284=disease activity score in 28 joints
after 4 months of treatment initiation±1 to 2 months, IgM RF= immunoglobulin M rheumatoid factor.
Table 2
Association of thyroid disorders with sex, disease duration, IgM
RF, anti-CCP, ANA, DDAS28, and EULAR response criteria in






Age, mean±SD 65.7±13.6 64.4±15.3 .50
Female sex, % 55 (79.7%) 209 (56.5%) <.001
Disease duration at time of data
extraction, mean±SD
2.6±1.8 2.6±1.6 .89
IgM RF positive, % 35 (50.7%) 209 (56.5%) .38
Anti-CCP ≥100EU/mL, % 34 (49.3%) 136 (36.7%) .05
ANA positive, % 20 (29%) 65 (17.6%) .04
DAS281, mean±SD 4.3±1.2 4.4±1.3 .62
DAS284, mean±SD 3.4±1.1 2.9±1.1 .006
DDAS28, mean±SD 1.0±1.4 1.5±1.4 .02
Eular response criteria, % .004
Good response 17 (24.6%) 123 (33.2%)
No response 28 (40.6%) 74 (20%)
DDAS28=DAS281 (at the time of diagnosis)DAS284 (after 4 months of treatment initiation±1–2
months), ANA=antinuclear antibody, anti-CCP= anticyclic citrullinated peptide antibody, EULAR=
European League Against Rheumatism, IgM RF= immunoglobulin M rheumatoid factor, SD=
standard deviation.
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patients was signiﬁcantly associated with female sex, ANA
positivity, and anti-CCP ≥100EU/mL; and the initial treatment
response was signiﬁcantly poorer among RA patients with
thyroid disorders, regardless of thyroid disorders subgroups,
compared with the patients with isolated RA that was of great
interest in this study.
Our results were consistent with previous ﬁndings conﬁrming
that thyroid disorders were more prevalent in patients diagnosed
with RA[8]; however, there were some inconsistencies. A study by
Bianchi et al[23] showed that thyroid disorders presented
irrespective of disease activity. This probably occurred due to
different disease activity assessment. Shiroky et al in a cohort
study of 119 RA patients, evaluating the association of thyroid
dysfunction in RA, did not ﬁnd any association between thyroid
disorders and age, RF, and also ANA.[10] Our results also
conﬁrmed that there was no association between presence of
thyroid disorders in RA patients and age, and also IgM RF;
however, we think that small difference between our results and
Shiroky et al’s results was caused by methodological or
laboratory analysis differences. Our results were in line with a
recent study by Joshi et al[24] and illustrated that there was a
signiﬁcant correlation between disease activity (at the time of
diagnosis) and thyroid disorders among RA patients. A
population-based, case-control study (1998 adult cases vs
2252 controls) by Bengtsson et al[25] revealed that patients
treated with thyroxin (hypothyroidism) were at double risk of
both anti-CCP negative (odds ratio [OR] 2.1, 95% conﬁdence
interval [CI] 1.5–3.1) and anti-CCP positive (OR 1.9, 95% CI
1.4–2.6) RA. Cárdenas Roldán et al[9] found the prevalence of
autoimmune thyroid disease equal to 9.8% in a cross-sectional
study which evaluated 800 RA patients for concurrent autoim-
mune thyroid disease.
In a study by Koszarnyet al,[26] evaluating the relationship
between antithyroid antibody titers and selected parameters of
RA activity in 75 consecutive hospitalized patients with RA,
signiﬁcant positive correlations was observed between TPOAb
and DAS28, and also TGAb, and both CRP and erythrocyte
sedimentation rate (ESR). Apart from this, DAS28 was
signiﬁcantly higher among RA patients with TPOAb/TGAb
positive compared with patients with TPOAb/TGAb negative.
The relationship between female sex and thyroid disorders
among RA patients in this study was in agreement with the more
frequent female sex in both RA and thyroid disorders. The
signiﬁcant association between presence of thyroid disorders in
RA patients and ANA positivity, and also anti-CCP ≥100EU/mL
was suggestive of a more aggressive disease with poor outcome in
these patients. Earlier studies also revealed the expressive
correlation between aggressive RA and high anti-CCP titer,
and also ANA positivity.[27–29] Furthermore, statistically signiﬁ-
cant difference between DAS28-CRP after 4 months of treatment
initiation and DDAS28-CRP among RA patients with and
without thyroid disorders supported this point of view.
The effect of RA treatment on the thyroid autoimmunity is little
known. However, beneﬁts of biological treatment, that is, tumor
necrosis factor (TNF) inhibitors to regulate and even depress
thyroid autoimmunity, has been discussed recently, which
delineates the possible role of TNF-a in a shared pathology
between RA and thyroid autoimmunity. A study by Raterman
et al, on 138 consecutive adalimumab-treated patients with RA
who were naive for TNF-blocking agents, resulted in decreasing
thyroid autoantibodies, that is, TPOAb and also TSH. The
authors concluded that TNF inhibitors could improve thyroid
function in hypothyroid patients with RA (especially in patients
who were L-thyroxine-naive and TPOAb+).[30] Furthermore,
TNF inhibitors may regulate expression of proinﬂammatory
cytokines and apoptosis in thyroids, leading to reduce level of
inﬂammation, earlier resolution, and decreased ﬁbrosis.[31]
Further investigations are still needed to enlighten the effect of
TNF inhibitors on thyroid autoimmunity.
It has been accepted that early diagnosis of RA along with
initiating treatment at early stage of the disease is decisive to
prevent further joint destruction. The ﬁrst few months after
treatment initiation are critical for long-term outcome.[14] The
lower disease activity achieved at 6months will result in the better
long-term outcome. A clinical remission within 3 to 6 months,
regardless of treatment regime, stops the progression of joint
damage.[15,16] In fact, the concept of 4 months follow-up and
DDAS28-CRP in the current study was implemented on the
signiﬁcance of ﬁrst few months after treatment initiation.
However, longer follow-up period, for example, at 6 or 12
months, is worth considering in future studies.
The shared susceptibility genes involved in the pathogenesis of
RA and thyroid disorders are HLA gene complex including HLA-
DR-B1 (human leukocyte antigen DR B1), CTLA 4 (cytotoxic T-
lymphocyte-associated antigen 4), PTPN22 (protein tyrosine
phosphatase non-receptor type 22), FCRL3 (Fc receptor-like 3),
and IL2RA (interleukin 2 receptor subunit alpha).[32] On the
contrary, previous studies elucidated that the carriership of HLA
gene complex is associated with anti-CCP positivity and therefore
more aggressive disease. In this study, the higher percentage of
anti-CCP ≥100EU/mL in RA patients with thyroid disorders not
only supports the role of genetic factors in the pathogenesis of
thyroid disorders and RA, but also explains the poorer initial
response to the RA treatment in these patients.[33]
This study had some limitations as we only selected newly
diagnosed RA patients (based on the new 2010 ACR/EULAR
criteria) between January 2010 and December 2015, selection
bias might be occurred. This is especially relevant for the
association of thyroid disorders in RA patients and disease
duration, since 1 of the possible hypothesis could be that patients
with longer duration of disease are exposed to higher rate of
comorbidities, for example, thyroid disorders compared with
newly diagnosed patients. The above mentioned bias can be
prevented by including all RA patients regardless of diagnosis
year. On the contrary, the individual medical records form family
physicians were not examined in this study since patients with
mild disease may not being referred to the hospital. In addition,
thyroid disorders diagnosed longer than 10 years ago were not
identiﬁed in this study. Therefore, the prevalence of thyroid
disorders might have been even higher. The results of this study
have a high degree of generalizability due to a feasible sample size
and broad inclusion criteria.
Table 3
Subgroups of thyroid disorders in the rheumatoid arthritis patients
together with DDAS28 for each subgroup.
Types of thyroid





Overt hypothyroidism 21 (30.4) 1.4±1.3 P= .36
Overt hyperthyroidism 7 (10.1) 0.1±0.9
Goiter 13 (18.8) 0.6±1.2
Autoimmune thyroiditis 10 (14.5) 1.3±1.5
Subclinical hypo/hyperthyroidism 18 (26.1) 0.8±1.4
DDAS28=DAS281 (at the time of diagnosis)DAS284 (after 4 months of treatment initiation±1–2
months), ANOVA=analysis of variance, DAS28=disease activity score in 28 joints.
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Our results indicate that the presence of thyroid disorders can
indirectly affect the prognosis of RA, possibly because of the
poorer treatment response. We propose routine measurement of
serum TSH in all RA patients at the time of diagnosis and with
yearly interval thereafter. This strategy will detect thyroid
disorders at an earlier stage, leading to early treatment initiation
and possibly better prognosis.
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